Abstract
Background The epidemiology of the Coronavirus-disease associated mucormycosis (CAM) syndemic is poorly elucidated. We aimed to identify risk factors that may explain the burden of cases and help develop preventive strategies.
Methods We performed a case-control study comparing cases diagnosed with CAM and those who had recovered from COVID-19 without developing mucormycosis (controls). Information on comorbidities, glycemic control, and practices related to COVID-19 prevention and treatment was recorded.
Results 352 patients (152 cases and 200 controls) diagnosed with COVID-19 during April-May 2021 were included. In the CAM group, symptoms of mucormycosis began a mean 18.9 (SD 9.1) days after onset of COVID-19, and predominantly rhino-sinus and orbital involvement was present. All, but one, CAM cases carried conventional risk factors of diabetes and steroid use. On multivariable regression, increased odds of CAM were associated with the presence of diabetes (adjusted OR 3.5, 95%CI 1.1-11), use of systemic steroids (aOR 7.7,95% CI 2.4-24.7), prolonged use of cloth and surgical masks (vs no mask, aOR 6.9, 95%CI 1.5-33.1), and repeated nasopharyngeal swab testing during the COVID-19 illness (aOR 1.6,95% CI 1.2-2.2). Zinc therapy, probably due to its utility in immune function, was found to be protective (aOR 0.05, 95%CI 0.01-0.19). Notably, the requirement of oxygen supplementation or hospitalization did not affect the risk of CAM.
Conclusion Judicious use of steroids and stringent glycemic control are vital to preventing mucormycosis. Use of clean masks, preference for N95 masks if available, and minimizing swab testing after the diagnosis of COVID-19 may further reduce the incidence of CAM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None to declare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institute Ethics Committee of AIIMS, Ansari Nagar, Delhi, India on 28/05/2021. The reference number for the approval is IECPG-353/28.05.21.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail ID: umangarora{at}gmail.com
E-mail ID: mpvision96{at}gmail.com
E-mail ID: katiyar.varidh{at}gmail.com
Email ID: manishsoneja{at}gmail.com
E-mail ID: drgargprerna{at}gmail.com
E-mail ID: ishan17gupta{at}gmail.com
E-mail ID: vishweshbharadiya000{at}gmail.com
E-mail ID: parulberry19{at}gmail.com
E-mail ID: tamoghnaghosh98{at}gmail.com
E-mail ID: lajja.patel01{at}gmail.com
E-mail ID: radhikasarda22{at}gmail.com
E-mail ID: drshreyagarg{at}gmail.com
E-mail ID: shubham.sfc99{at}gmail.com
E-mail ID: veronicaarora{at}gmail.com
E-mail ID: aishwarya.dec{at}gmail.com
E-mail ID: mitugarg75{at}gmail.com
E-mail ID: drrohitkgarg{at}gmail.com
Email ID: parulkodan{at}yahoo.com
Email ID: neerajnischal{at}gmail.com
Email ID: drgagandeep{at}gmail.com
Email ID: pankajjorwal.aiims{at}gmail.com
Email ID: linktoarvind{at}gmail.com
Email ID: drupendraraj14{at}gmail.com
Email ID: vpmahar05{at}gmail.com
Email ID: doctoranimeshray{at}gmail.com
Email ID: prayassethi82{at}gmail.com
Email ID: immaxess{at}gmail.com
Email ID: navalvikram{at}gmail.com
Email ID: drsanjeevsinha{at}gmail.com
Email ID: asuaiims{at}gmail.com
Email ID: drathakar{at}gmail.com
Email ID: sushmabhatnagar1{at}gmail.com
Email ID: anjantrikha{at}hotmail.com
Email ID: naveetwig{at}gmail.com
Availability of data and materials The data would be made available by the authors on specific requests keeping patient confidentiality in view.
IRB approval The study was approved by the Institute Ethics Committee of AIIMS, Ansari Nagar, Delhi, India on 28/05/2021. The reference number for the approval is IECPG-353/28.05.21.
Competing interests The authors declare that they have no competing interests.
Data Availability
Data will be available upon request to the corresponding author, along with a proposed research question explaining the request for data.